ClinicalTrials.gg
CompletedNCT03100591Updated Nov 29, 2022

A Study to Evaluate ACT-132577 in Healthy Male Subjects

A Phase 1 interventional study of 14C-radiolabeled ACT-132577 in Healthy Subjects, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 1 site in Netherlands. Open to male participants aged 45 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-29.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
45 Years to 65 Years
Sex
Male
01

Study summary

The primary purpose of this study is to investigate the rate and routes (urine and feces) of elimination of ACT-132577, and the mass balance in urine and feces

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.

Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed in a language understandable to the subject prior to any study-mandated procedure;
  • Healthy male subjects aged between 45 and 65 years (inclusive) at screening;
  • of 18.0 to 28.0 kg/m2 (inclusive) at screening;
  • Healthy on the basis of physical examination, cardiovascular assessments and laboratory tests.

Exclusion criteria

Exclusion Criteria:

  • Values of hepatic aminotransferase ( and/or aspartate aminotransferase) > 3 × at screening;
  • \< 100 g/L at screening;
  • Known to ACT-132577 or drugs of the same class, or any of the ACT-132577 drug formulation;
  • Known hypersensitivity or allergy to natural rubber latex;
  • Previous exposure to ACT-132577;
  • Treatment with another drug within 3 months prior to screening or participation in more than 4 investigational drug studies within 1 year prior to screening;
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol;
  • A radiation burden of > 0.1 milliSievert (mSv) and ≤ 1.0 mSv in the period of 1 year prior to screening; a radiation burden of ≥ 1.1 mSv and ≤ 2.0 mSv in the period of 2 years prior to screening, etc. (add 1 year per 1 mSv).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    14C-radiolabelled ACT-132577

    On Day 1, subjects will receive a single oral dose of 25 mg 14C-radiolabeled ACT-132577, administered as an oral formulation in the fasted state

    Drug: 14C-radiolabeled ACT-132577

Interventions

  • Single oral dose of 3.7 megabecquerel (MBq) (100 microcurie \[μCi\]) 14C-radiolabeled ACT-132577 administered as 1 capsule of 25 mg

    Also known as: Aprocitentan

06

What researchers measure

Primary outcomes

  1. Cumulative excretion of radioactivity in urine and feces

    14C-radioactivity will be measured daily in urine and feces samples for determination of total radioactivity recovery

    Time frame: From study treatment administration up to day 15

Secondary outcomes

  1. Number of subjects with treatment-emergent adverse events and serious adverse events

    Collection of any adverse event at each dose level

    Time frame: From study treatment administration up to day 32

  2. Maximum plasma concentration (Cmax) of 14C-radiolabeled ACT-132577

    Cmax is directly derived from the observed plasma concentrations of ACT-132577 and its metabolites

    Time frame: From study treatment administration up to day 15

  3. Time to reach Cmax (tmax) of 14C-radiolabeled ACT-132577

    tmax is directly derived from the observed plasma concentrations of ACT-132577 and its metabolites

    Time frame: From study treatment administration up to day 15

  4. Terminal half-life (t1/2) of 14C-radiolabeled ACT-132577

    t1/2 is calculated from the terminal rate constant obtained from the plasma concentrations-time curves of ACT-132577 and its metabolites

    Time frame: From study treatment administration up to day 15

  5. Area under the plasma concentration-time curve (AUC) of 14C-radiolabeled ACT-132577

    AUC is defined for the time intervals from zero to time t of the last measured concentration above the limit of quantification and from zero to infinity

    Time frame: From study treatment administration up to day 15

  6. Maximum plasma concentration (Cmax) of ACT-132577 and its metabolites

    Cmax is directly derived from the observed plasma concentrations of ACT-132577 and its metabolites

    Time frame: From study treatment administration up to day 15

  7. Time to reach Cmax (tmax) of ACT-132577 and its metabolites

    tmax is directly derived from the observed plasma concentrations of ACT-132577 and its metabolites

    Time frame: From study treatment administration up to day 15

  8. Terminal half-life (t1/2) of ACT-132577 and its metabolites

    t1/2 is calculated from the terminal rate constant obtained from the plasma concentrations-time curves of ACT-132577 and its metabolites

    Time frame: From study treatment administration up to day 15

  9. Area under the plasma concentration-time curve (AUC) ACT-132577 and its metabolites

    AUC is defined for the time intervals from zero to time t of the last measured concentration above the limit of quantification and from zero to infinity

    Time frame: From study treatment administration up to day 15

07

Study locations

1 site
  • PRA Health Sciences
    Groningen, Netherlands
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Apr 2017, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2017
First posted
Apr 4, 2017
StartActual
Mar 28, 2017
Primary completionActual
Apr 18, 2017
CompletionActual
Apr 18, 2017
Last update
Nov 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03100591
Responsible party
Sponsor
First posted
Apr 4, 2017
Start date
Mar 28, 2017
Primary completion
Apr 18, 2017
Completion
Apr 18, 2017
Last update
Nov 29, 2022

Study contacts

Clinical Trials
study director · Idorsia Pharmaceuticals Ltd.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aprocitentan

Start the discussion